Sivik Global Healthcare’s Sage Therapeutics SAGE Stock Holding History

Sivik Global Healthcare’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-15,000	Closed	-$1.08M	–	55
2019 Q4	$1.08M	Buy	15,000 +5,000	+50%	+$615K	0.4%	49
2019 Q3	$1.4M	Sell	10,000 -7,500	-43%	-$1.25M	0.71%	40
2019 Q2	$3.2M	Buy	17,500 +7,500	+75%	+$1.28M	0.77%	39
2019 Q1	$1.59M	Hold	10,000	–	–	0.59%	54
2018 Q4	$958K	Hold	10,000	–	–	0.52%	42
2018 Q3	$1.41M	Sell	10,000 -15,000	-60%	-$2.32M	0.5%	56
2018 Q2	$3.91M	Buy	25,000 +10,000	+67%	+$1.57M	1.5%	34
2018 Q1	$2.42M	Sell	15,000 -5,000	-25%	-$849K	1.13%	39
2017 Q4	$3.29M	Buy	+20,000	New	+$1.94M	1.22%	38
2017 Q3	–	Sell	-20,000	Closed	-$1.59M	–	85
2017 Q2	$1.59M	Hold	20,000	–	–	0.58%	58
2017 Q1	$1.42M	Hold	20,000	–	–	0.66%	51
2016 Q4	$1.02M	Buy	+20,000	New	+$943K	0.49%	48
2015 Q3	–	Sell	-13,000	Closed	-$949K	–	66
2015 Q2	$949K	Buy	+13,000	New	+$836K	0.33%	68

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Sivik Global Healthcare's SAGE Position: Q1 2020 in Review

Sivik Global Healthcare sold out of Sage Therapeutics (SAGE) in Q1 2020, closing a stake of 15,000 shares — an estimated $1.08M sold.

Sivik Global Healthcare first reported a position in SAGE in Q2 2015 and held it in 13 quarters. The position peaked at $3.91M in Q2 2018. 230 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

Sivik Global Healthcare reported no remaining Sage Therapeutics position as of Q1 2020 after selling out during the quarter.
Sivik Global Healthcare sold 15,000 Sage Therapeutics shares in Q1 2020, an estimated $1.08M.
Sivik Global Healthcare first reported a position in Sage Therapeutics in Q2 2015 and held it in 13 quarters.
Sivik Global Healthcare's Sage Therapeutics position peaked at $3.91M in Q2 2018.
230 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on Sivik Global Healthcare's 13F filing for Q1 2020, filed 15 May 2020.